Differential scanning calorimetry (DSC) of blood serum in chronic obstructive pulmonary disease (COPD) A new diagnostic tool ahead?

• Published in: Journal of thermal analysis and calorimetry Vol. 113; no. 1; pp. 259 - 264
• Main Authors: Szalai, Zsuzsanna, Molnár, Tamás F., Lőrinczy, Dénes
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.07.2013
• Subjects: Analytical Chemistry; Chemistry; Chemistry and Materials Science; Inorganic Chemistry; Measurement Science and Instrumentation; Physical Chemistry; Polymer Sciences; Chronic obstructive pulmonary disease (COPD); Global initiative for chronic obstructive lung disease (GOLD); Differential scanning calorimetry (DSC); COPD severity
• ISSN: 1388-6150; 1572-8943
• DOI: 10.1007/s10973-013-2999-1

Chronic obstructive pulmonary disease (COPD) is a major global health challenge with a gloom perspective of being one of the big three cause of death by 2020. No reliable/reproducible biomarker has been identified so far to match the clinically-based staging system (GOLD). Blood samples of 30 subjects divided into 6 groups (no-COPD/-smoker, no-COPD/non-smoker, COPD I, COPD II, COPD III, COPD IV) with 5 patients in each were tested by differential scanning calorimetry. There is a clear 15.4 % difference between the heat flow maxima measured when no-COPD subjects were compared in accordance to their smoking/non-smoking status. Odds ratio of different heat flow in actively smoking COPD patients in stage IV and stage I was 1.61. A reverse tendency is detected in the relevant non-smoking COPD groups. The differences are inconsistent in intermediate stages (COPD II and III). DSC seems to be an applicable and objective method for monitoring nicotine abuse. There is a chance to detect specific typology of thermokinetic patterns in the two extremes of COPD (I vs. IV). Further studies with increased sample size are needed to allow calculations on specificity/sensitivity/positive and negative predictive value of enthalpies and heat flow maximums. The first clinically relevant blood-based COPD marker on the intravascular side of the alveo-capillary screen is demonstrated by our pilot study.